Heartflow (NASDAQ:HTFL) Stock Gets Price Target Boost from Canaccord Genuity Group

Heartflow (NASDAQ:HTFL) had its target price boosted by investment analysts at Canaccord Genuity Group from $56.00 to $69.00 in a report released on Friday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Canaccord Genuity Group‘s price target indicates a potential upside of 42.39% from the stock’s current price.

HTFL has been the subject of several other research reports. UBS Group initiated coverage on Heartflow in a report on Wednesday, September 9th. They set a “neutral” rating and a $55.00 price target for the company. Piper Sandler reissued an “overweight” rating and issued a $64.00 price objective (up from $45.00) on shares of Heartflow in a research report on Tuesday, October 20th. Wells Fargo & Company raised their target price on shares of Heartflow from $37.00 to $39.00 and gave the stock an “overweight” rating in a research note on Friday, August 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Heartflow in a report on Wednesday, November 4th. Finally, Morgan Stanley upped their price target on shares of Heartflow from $35.00 to $40.00 and gave the company an “equal weight” rating in a research note on Friday, August 14th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $60.12.

Heartflow Trading Down 19.1%

NASDAQ:HTFL traded down $11.46 on Friday, hitting $48.46. The company’s stock had a trading volume of 3,705,135 shares, compared to its average volume of 1,763,967. Heartflow has a one year low of $20.13 and a one year high of $60.65. The firm has a market capitalization of $4.21 billion, a P/E ratio of -52.67 and a beta of 2.50. The stock has a fifty day moving average of $51.91 and a two-hundred day moving average of $35.23.

Heartflow (NASDAQ:HTFL) last issued its earnings results on Thursday, November 12th. The company reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.15. The company had revenue of $72.86 million during the quarter. Heartflow had a negative return on equity of 20.42% and a negative net margin of 33.11%. During the same quarter in the prior year, the firm posted ($0.27) earnings per share. As a group, sell-side analysts anticipate that Heartflow will post -0.75 EPS for the current year.

Insider Buying and Selling at Heartflow

In other Heartflow news, CFO Vikram Verghese sold 29,714 shares of the stock in a transaction on Friday, September 11th. The stock was sold at an average price of $50.06, for a total transaction of $1,487,482.84. Following the transaction, the chief financial officer owned 184,789 shares in the company, valued at $9,250,537.34. This trade represents a 13.85% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Campbell Rogers sold 23,933 shares of Heartflow stock in a transaction on Thursday, October 22nd. The stock was sold at an average price of $55.01, for a total value of $1,316,554.33. Following the sale, the insider directly owned 73,453 shares of the company’s stock, valued at $4,040,649.53. This represents a 24.58% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 332,403 shares of company stock valued at $16,602,786 in the last ninety days. 7.70% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Marshall Wace LLP bought a new position in shares of Heartflow during the third quarter worth approximately $292,000. Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in shares of Heartflow in the third quarter valued at approximately $24,874,000. State Board of Administration of Florida Retirement System boosted its stake in shares of Heartflow by 7.5% in the third quarter. State Board of Administration of Florida Retirement System now owns 10,671 shares of the company’s stock valued at $531,000 after buying an additional 740 shares during the period. First Trust Advisors LP bought a new stake in shares of Heartflow in the third quarter valued at approximately $1,931,000. Finally, Teachers Retirement System of The State of Kentucky acquired a new stake in Heartflow during the third quarter worth approximately $1,684,000.

Heartflow News Summary

Investors following HTFL have been watching these news items:

• Positive Sentiment: Q3 revenue rose 57% year over year to $72.9 million, above the roughly $65.2 million consensus. The quarterly loss was $0.03 per share, narrower than analysts’ expected $0.18 loss and the $0.27 loss a year earlier. Q3 results
• Positive Sentiment: Heartflow raised its 2026 revenue guidance to $262 million–$264 million, above the approximately $248.5 million consensus, signaling stronger expected growth. Financial results and guidance
• Positive Sentiment: Wells Fargo, Canaccord Genuity, Stifel and Baird raised their price targets to $68–$70 and maintained positive ratings, reflecting improved analyst expectations. Wells Fargo rating Canaccord Genuity rating Stifel rating Baird rating

Heartflow Company Profile

HeartFlow, Inc. is a medical technology company that develops noninvasive tools to help clinicians assess coronary artery disease. Its platform analyzes coronary CT angiography scans to create personalized models of a patient’s coronary arteries and provide information that can support diagnosis and treatment planning. The company’s offerings include HeartFlow FFR CT Analysis, which estimates blood flow and the effects of artery narrowing, and tools for assessing coronary plaque. The technology combines medical imaging with computational analysis and artificial intelligence, giving clinicians information without requiring an invasive procedure to measure blood flow.